Introduction
After prolonged and profound suppression of human pituitary-adrenal function by cortisol-like steroids, there is frequently a delay of several months before normal function is regained (1) . The course of recovery is characterized by an initial phase in which both adrenocorticotropic hormone and cortisol concentrations in the blood are subnormal. Then there is an intermediate phase during which ACTH increases to concentrations that are normal or greater, but adrenocortical responsiveness to ACTH remains subnormal. In the final phase, normal adrenocortical responsiveness is regained, so that cortisol is secreted in normal quantities in response to normal concentrations of ACTH in the plasma.
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t Address requests for reprints to Dr. Grant W. Liddle, Vanderbilt University School of Medicine, Nashville, Tenn. 37203. pression and who were then treated intermittently with depot preparations of porcine ACTH in an effort to hasten their recovery of adrenocortical responsiveness. Unfortunately, this treatment did not shorten the period of pituitary-adrenal recovery, but in the course of the treatment we observed that all six patients developed neutralizing antibodies to porcine ACTH. These antibodies cross-reacted with endogenous human ACTH, binding it in the circulation in inactive form.
Studies were performed, first, to characterize the antibodies and, second, to determine whether their presence in the circulation seriously modified pituitary-adrenal function. For the latter purpose, additional observations were made in three patients who had received repeated injections of depot porcine ACTH without having undergone prior pituitary-adrenal suppression. Two of these patients were also found to have antibodies to ACTH.
Methods
Clinical. The principal group of patients were six individuals who had experienced continuous pituitaryadrenal suppression for at least 1 year before study. In four patients the suppression was the result of cortisol secretion by an adrenocortical tumor. The other two had 196 been treated with supraphysiological doses of cortisol analogues for rheumatoid arthritis. The degree of corticosteroid excess was sufficient to induce Cushing's syndrome in all six patients. The degree and duration of pituitary-adrenal suppression were comparable to those of the larger group previously reported from this laboratory by Graber and associates (1) (1) . However, the degree of elevation was much more striking in the patients of the present study who had received courses of treatment with depot porcine ACTH.
The following evidence indicated that the ACTH in the plasma of the treated patients was endogenous. 1) High concentrations of ACTH were found even though blood was not drawn for assay until 1 to 3 weeks after the last previous injection of porcine ACTH. Although plasma ACTH concentrations were much higher in patients who had received depot porcine ACTH than in those who had not, the plasma and urinary 17-OHCS were similar in the two groups. This suggested the possibility that much of the ACTH in the plasma of the ACTHtreated patients was circulating in an inactive form. This idea was corroborated by the further finding that adrenal secretory activity, although low in most of the patients, could be increased in all cases by giving infusions of exogenous ACTH. Previous studies (9) have indicated that concentrations of plasma ACTH slightly in excess of 3 mU per 100 ml will induce maximal adrenal secretory activity. Even though the ACTH content of the plasma of our patients ranged as high as 150 mU per 100 ml, their adrenal glands were not maximally stimulated. In the absence of exogenous ACTH the urinary 17-hydroxycorticosteroids of these patients ranged from 2 to 6 mg per day, but in response to 50 U of ACTH administered as a constant intravenous infusion for 8 hours, the urinary 17-hydroxycorticosteroids rose to 6 to 23 mg per day.
A possible explanation for the ineffectiveness of the high concentrations of endogenous ACTH in the plasma of our patients was derived from some previous studies of animals that had deliberately been immunized with ACTH. It had been observed that, in the presence of neutralizing antibodies, circulating ACTH could be present in high titers without stimulating adrenal secretion. By acidification of the plasma, however, the antibody- tions of total plasma ACTH were made on four patients with ACTH antibodies (S.J., E.C., M.J., J.W.), one Addisonian patient (V.WV.), and one normal subject treated with metyrapone, 250 mg per hour for 36 hours (W.C.). Patient S.J. was studied on three separate occasions. We used dexamethasone to suppress ACTH secretion in order to simplify the study of plasma ACTH disappearance rates. The initial concentrations of ACTH in the plasma, in milliunits per 100 ml, were as follows: S.J. (1) In all experiments each rat received 0.20 mU of porcine or human ACTH. The height of each bar represents the mean corticosterone secretion induced in hypophysectomized rats by the ACTH. The brackets represent standard errors of the means. In control experiments the ACTH was incubated in normal serum. In the other experiments the ACTH was incubated in serum obtained from patient S.J. in the dilution shown above each bar. We gave this patient dexamethasone for 5 days before the time her serum was obtained to reduce the serum ACTH content to negligible values.
tralizing and ACTH-131I-binding properties of immune sera resided in the -y-globulin fraction (as would be expected if they were properties of specific antibodies), we subjected 0.5 ml of serum of patient S.J. to paper electrophoresis. The electrophoretic strips were then cut into portions corresponding to the albumin, a-globulin, and /8-plus y-globulin fractions. The proteins were eluted from the paper with a phosphate buffer containing 0.5%S bovine globulin, and the fractions were tested for their capacity to neutralize the biologic activity of ACTH and to bind ACTH-'31I. Only the /8-plus y-globulin fraction had appreciable ACTH-neutralizing or ACTH-131I-binding capacity (Table II) .
Effects of temperature. The ACTH-neutralizing capacity of immune sera was not appreciably affected by prior heating at 560 C for 36 minutes, indicating that complement is not essential for the in vitro reaction of antiserum with ACTH (11). Immune sera were effective in neutralizing ACTH whether incubation was carried out at 37 or 40 C.
Pituitary-adrenal dynamics in the presence of ACTH antibodies Subsequent discussion will utilize the terms "free ACTH" to denote that detectable in unacidified plasma and "total ACTH" to indicate that detectable in acidified or acid-extracted samples of plasma. As indicated in Table I , group II, in the absence of ACTH antibodies, free ACTH and total ACTH are probably identical. Ag of unlabeled (cold) ACTH to the incubation mixture displaced the labeled hormone from the globulin fraction so that it remained at the origin with free ACTH.
Rate of disappearance of plasma total ACTH. Several experiments were performed to determine the relative rates of disappearance of total ACTH from the plasma of patients with neutralizing antibodies and of those without such antibodies (Figure 3) . Of the two patients without antibodies, one had high plasma ACTH concentrations because of untreated Addison's disease, the other because of treatment with 250 mg of metyrapone 4 per hour for the preceding 36 hours. When 2 mg of dexamethasone phosphate was administered intravenously to these individuals, ACTH disappeared rapidly from their plasma with "halftimes" of several minutes. In contrast, four patients (six studies) with high concentrations of bound ACTH in their plasma responded to dexamethasone (2 mg intravenously, followed by 1 mg orally every 6 hours) with very slow decreases in plasma ACTH concentration, with half-times of several hours. After dexamethasone was discontinued, ACTH concentrations returned to predexamethasone values, confirming the view that the ACTH was endogenous.
Lack of diurnal rhythm in total ACTH. Total ACTH concentrations in the plasma of patients with ACTH antibodies failed to exhibit a diurnal 4 Metopirone, Ciba Pharmaceutical Co., Summit, N. J. variation ( Figure 6 ). This lack of an obvious diurnal rhythm in total ACTH concentrations stands in contrast to what has been observed in normal subjects and in cortisol-deficient patients who have not received depot porcine ACTH (1, 12) . Diurnal rhythm in plasma 17-OHCS and free ACTH. Patients with ACTH antibodies did exhibit a diurnal variation in plasma 17-OHCS (Table III). In the two patients (S.J. and J.W.) in whom free ACTH was detectable, there was a consistent diurnal variation in both free ACTH and plasma 17-OHCS. This would suggest that adrenal steroidogenesis in vivo is dependent on the level of free rather than total ACTH and that the level of free ACTH is not a constant function of the level of total ACTH.
Pituitary-adrenal function in nonsuppressed patients with ACTH antibodies. The possibility that the presence of ACTH antibodies might seriously impair pituitary-adrenal function was difficult to evaluate in patients convalescing from prolonged pituitary-adrenal suppression, because adrenal responsiveness was subnormal in that situation. Therefore, studies were performed in two patients (E.C. and F.S.) who had received intermittent injections of depot porcine ACTH over long periods but who had never received suppressive doses of corticosteroids. Free ACTH was not detectable in their plasma (less than 1 mU per 100 ml). Plasma and urinary 17 (4, (13) (14) (15) (16) . Previous evidence of the antigenicity of ACTH in human subjects has been published in the form of reports of allergic reactions to impure preparations of ACTH (17) (18) (19) . Although certain of these studies provided strong evidence for antibodies to pituitary substances, it was not possible to state whether the antibodies were formed in response to ACTH or to impurities in the ACTH preparations. None of our patients demonstrated clinical allergic manifestations when treated with ACTH.
The evidence that the patients of the present study developed specific antibodies to ACTH may be summarized as follows. 1) Sera from these patients possessed the capacity to neutralize human and porcine ACTH in vitro, a property which resided in the /8-plus y-globulin fraction. 2) Sera from these patients bound ACTH-1311 to the globulin fraction, and the bound ACTH-1311 could be displaced by the addition of a small excess of unlabeled ACTH but not by the addition of other polypeptides. 3) Large amounts of ACTH were bound in inactive form in the plasma of these patients. 4) Individuals who had not received repeated injections of depot porcine ACTH did not develop sera that would neutralize ACTH or bind ACTH-131I.
The high incidence of antibodies to ACTH (eight of nine patients studied) is analogous to what has been reported in patients receiving insulin (20) .
The binding of ACTH to antibody appears to protect it from in vivo destruction as judged by the prolonged plasma half-time of total ACTH.
Circulating insulin that is bound to insulin antibodies also has a prolonged rate of disappearance from plasma (21) .
In order to ascertain the effects of circulating ACTH antibodies on pituitary-adrenal function, it is necessary to consider the immunized patients in two groups and compare them with appropriate nonimmunized control subjects. One group, those who were convalescing from prolonged pituitaryadrenal suppression, were similar to the suppressed nonimmunized patients reported previously in passing through three stages of recovery, the second of which was characterized by elevated concentrations of free ACTH in the plasma (1). They were also similar in their sluggish recovery of adrenal responsiveness and in their exhibition of a diurnal variation in free ACTH and in plasma 17-OHCS with higher levels in the morning than in the evening. This group differed from their nonimmunized counterparts in having a greatly delayed rate of disappearance of total ACTH from plasma. The other group, those who had been immunized to ACTH without previously undergoing pituitary-adrenal suppression, differed from normal subjects in having a greatly delayed rate of disappearance of total ACTH from the plasma but resembled normal subjects in exhibiting definite diurnal variations in plasma 17-OHCS, in responding with increased excretion of 17-OHCS when treated with ACTH or with metyrapone, and in responding with decreased excretion of 17-OHCS when treated with dexamethasone. It must be concluded that the mere presence of ACTH antibodies does not grossly alter pituitary-adrenal interrelationships even though subtle changes can be demonstrated.
Although the presence of ACTH antibodies may not constitute a significant physiological problem for the patient, it does pose potential problems for the clinical physiologist who assays ACTH, whether the assays are performed by biological or immunological techniques.
